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1. Introduction: 
1.1 Cancer 
 Cancer is the one of the most formidable burdens facing the United States, and other 
developed countries today. It is the leading cause of death worldwide that accounted for 7.6 
million deaths in 2008, a number projected to increase in the future [1]. Current thought 
attributes carcinogenesis to a multi-step process of genetic and epigenetic abnormalities of 
normal cells [2]. Although progressive cancers have proven difficult to treat, cancer is a largely 
preventable disease, and through early detection and screening favorable prognosis ensues [2]. 
More than half of cancers can be prevented by avoiding exposure to carcinogens such as 
cigarette smoking, recurrent infections, and protection from excessive sun exposure and 
reductions in occupational and environmental toxins [3]. 
Of the vast type’s cancers, lung cancer boasts both the highest rate of incidence and 
mortality [1]. Nearly 60% of individuals diagnosed with lung cancer die within a year of 
diagnosis. Adding to the lethality of the disease, there are few currently implemented screening 
methods for lung cancer and early detection markers are still being studied [4]. Also, many of the 
symptoms associated with lung cancer are common in other less serious conditions. There are 
two major types of lung cancer, small cell lung cancer (SCLC) and the more common non-small 
cell lung cancer (NSCLC), as characterized by histology. The faster growing and less common 
SCLC is further divided into three different types: small cell carcinoma, mixed small cell/large 
cell carcinoma and combined small cell carcinoma.  SCLC is almost always caused by cigarette 
smoking. It metastasizes quickly form the bronchial tubes and is responsible for 15% of all lung 
cancer cases.  NSCLC is also found in three different forms arising in different parts of the lungs. 
Adenocarcinomas are found in the outer area of the lung, squamous cell carcinomas are in the 
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center of the lung, near an air tube, and large cell carcinomas form throughout. Although more 
prevalent, NSCLC grows slower than its counterpart and is caused by smoking, pollution, arsenic 
and other environmental risk factors [5].  
The molecular characteristics of NSCLC, include overexpression of nuclear factor-
kappaB (NFκB). NFκB is a transcription factor that has been shown to play a role in cell 
proliferation and oncogenesis. Studies correlated NFκB expression with lung cancer 
differentiation in which higher expression of the transcription factor was inversely proportional 
to apoptotic rate [6]. The same study also observed a correlation of NFκB expression with 
cyclooxygenase-2, tumor suppressor p53 and the executioner of apoptosis caspase-3.   
Furthermore, the stress activated serine-threonine casein kinase 2 (CK2) is overexpressed in 
NSCLC and is correlated to a poor prognosis [7]. CK2 phosphorylation of its targets leads to the 
proliferation and morphology characteristic of NSCLC. Inhibitors of CK2 have incurred interest  
as potential anti-cancer drugs [8, 7]. 
After characterization, staging of the cancer is pivotal in determining the prognosis [9, 5]. 
Lung cancer is staged depending on the size of the tumor, proximity of the tumor to lymph nodes 
and whether the cancer has spread to different parts of the body.  Depending on the stage of the 
cancer, proper therapy is chosen which ranges from surgical removal of lung portions, to 
chemotherapy and radiation therapy. However, where surgery is not an option, prolonged 
chemotherapy and radiation compromise the immune system of the patient, leaving the body 
susceptible to other diseases and infections. Thus novel and more effective therapeutic strategies 
are needed in the control of metastasis as well as growth of pulmonary cancers.    
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1.2 Flavonoids 
In recent years, exercise regimes along with healthy diets have been shown to be 
effective in cancer prevention. Essential in healthy eating is a plant-based diet, particularly in 
fruits and vegetables containing substantial quantities of molecules that have chemopreventaitive 
potential to fight against cancer development [10].  These compounds include vitamins, trace 
elements, carotenoids, flavonoids and many other components of leafy, green vegetables [11]. 
Such diets contain high consumption of parsley and celery which are rich in polyphenolic 
compounds [12]. Polyphenolic compounds, called flavonoids, are comprised of approximately 
5,000 substances defined chemically as having common phenlychromanone structure (C6-C3-
C6), with multiple hydroxyl functional groups [13, 14]. Flavonoids are further classified into 
flavones, flavanols, isoflavones, flavonols, flavonones and anthocyanins (Table 1) based on 
structural features and varying positions of functional groups. Two major features of flavonoids 
contributing to their beneficial health properties are their anti-oxidant properties and capabilities 
to interact with proteins [15]. The structural similarity between purines and certain flavonoids 
leads to flavonoid inhibition of ATP dependant enzymes including kinases, topoisomerases and 
ABC transporters [16, 17]. Flavonoids with estrogen like structures, like the isoflavones, make 
for potent receptor agonists, with significant implications for cancer therapy [18].  
The protective roles of bioactive molecules like flavonoids have been extensively noted 
in many studies. In the Zutphen study, cohorts of 878 men were followed for 25 years beginning 
in 1960, and monitored for incidence or mortality from all causes of cancer with the intake of 5 
flavonoids; apigenin myricetin, quercetin, kaempferol and luteoin. The results showed that high 
intake of flavonoids from vegetables and fruits was inversely associated with risk of cancer [19]. 
In a more recent study, patients with resected colon cancer and polypectomy were divided into  
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two groups, one receiving a flavonoid mixture (20 mg apigenin and 20 mg epigallocatechin-
gallate) and a control group. Patients receiving the flavonoid diet had significantly lower rates of 
cancer recurrence, and reduced recurrence rate of neoplasia in patients with sporadic colorectal 
neoplasia [20]. These studies affirm that flavonoids contain attractive, therapeutic capabilities; 
however there is much to learn about the cellular mechanisms by which they function.  
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1.3 Apigenin 
The flavone apigenin has incurred considerable interest for its attractive anti-
inflammatory, anti-proliferative and anti-carcinogenic properties, however the underlying 
mechanisms by which it acts are poorly understood. Apigenin (Figure 1a), chemically 4’,5,7,-
trihydroxyflavone (C15H10O5, MW 270.24), is also found naturally as biapigenin (Figure 1b) and 
is abundant is common in grapefruit, vegetables, parsley, onions, oranges, tea chamomile, and 
some seasonings [21,22]. The most abundant natural forms of apigenin are found in their 
glycoside form, where a sugar residue is conjugated to one of the hydroxyl groups (ex. apigenin-
7-O-glucoside) and various acylated derivatives (Figure 1c,d) [23]. 
 
 
 
 
 
 
The interest in apigenin stems both from its attractive effects on cancerous cells and its 
low toxicity in comparison with other related flavonoids [24]. Some of the biological effects of 
apigenin come from the molecule’s anti-oxidant and free radical scavenging abilities. Apigenin 
takes a protective role in murine studies were specimens were exposed to apigenin before 
carcinogenic insult [25]. Apigenin generates reactive oxygen species, causes loss of 
mitochondrial Bcl-2 expression, increases mitochondrial permeability, causes cytochrome c 
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release, and induces cleavage of caspase-3,-7,-8 and -9 which are crucial in the execution of 
programmed cell death, apoptosis [26]. Unlike its close predecessor naringenin, apigenin induces 
apoptosis in leukemia cells mediated by the activation of protein kinase C δ (PKC δ) [27]. 
Inhibition of protein kinase CK2, a serine-threonine kinase involved in cell cycle regulation by 
apigenin, involves the flavonoid in cell cycle regulation [28]. Apigenin is also a potent inhibitor 
of ornithine decarboxylase, an enzyme of the pyrimidine synthesis pathway heavily involved in 
tumor promotion. Further anti-carcinogenic abilities of apigenin were demonstrated with topical 
application of the flavonoid in dimethyl benzanthracene-induced skin tumors [29]. Other notable 
interactions of apigenin include telomerase [30] and fatty acid synthase [31] inhibition, matrix 
metalloproteinases [32], and suppression of cell cycle through aryl hydrocarbon receptor activity 
[33], all of which are relevant in different human diseases. 
The role of the flavone to down-modulate pro-inflammatory cytokines implicates it in 
inflammatory diseases. Monocytes are produced daily in bone marrow and circulate in the blood 
for 24-48 hrs before undergoing apoptosis [34]. However, this apoptotic fate is halted by 
inflammatory stimuli [35].  Pro-inflammatory cytokines, such as TNFα (Tumor necrosis factor), 
and stimulatory signals such as lipopolysaccharide (LPS), a component of gram-negative 
bacteria cell wall, inhibit the apoptotic program by promoting monocyte survival [34, 35].  This 
prolonged survival contributes to the maintenance and onset inflammation. Monocyte evasion of 
apoptosis and differentiation to macrophages is also relevant in solid cancers where macrophage 
infiltration has been linked to tumor progression [36]. Our group showed that apigenin inhibits 
the production of pro-inflammatory cytokines by down-modulating the transcriptional activity of 
NF- κB in stimulated monocytes and in a mouse model of acute inflammation [37].  
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The ability of apigenin to interject in many important cellular functions and its potential 
to be utilized as a therapeutic in both cancer and inflammation compound the need to elucidate 
the mechanisms by which it acts. In working towards finding apigenin’s mechanism of action, 
our lab used a phage-display breast cancer library, coupled with next generation sequencing and 
identified the heterogeneous nuclear ribonucleoprotein A2/B1 as a direct target of apigenin. 
1.4 Heterogeneous Nuclear Ribonucleoproteins 
 Heterogeneous nuclear 
ribonucleoptoteins (hnRNPs) are amongst 
the most abundant RNA-binding proteins 
which associate with nascent pre-mRNAs, 
thereby complexing them into hnRNP 
particles [38]. The family consists of more 
than 20 major polypeptides, A1 to U, 
ranging in sizes of 34 to 120 kDa which in 
accord are responsible for mRNA metabolism [38]. All hnRNP proteins contain nuclear 
localization signal (NLS) and at least one N-terminal RNA recognition motif (RRM) and a C-
terminal glycine-rich domain (GRD) (Figure 2). The C-terminal domain of the hnRNPs is crucial 
in mediating the protein’s functional properties through regulation of protein-protein interactions 
with other hnRNPs. This form of regulation has been implicated in the alternative splicing of 
target mRNAs, thereby favoring one splice variant over another [39]. The hnRNPA/B subfamily 
have high levels of complimetarity in sequences, most significantly in their structural motifs. 
Human hnRNPs A1 and A2 exhibit approximately 80% homology in their RRM and 58% in 
their GRD [39, 40]. The family is encoded by 10 human genes which due to their sequence 
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complimentarily, are thought have arisen form one single RNA-binding protein by gene 
duplication [39].  
1.4a Heterogeneous Nuclear Ribonucleoprotein A2 
 HnRNPA2 is the most abundantly expressed hnRNP proteins, compromising 60% of the 
protein family mass, along with hnRNPA1 [41]. Both proteins have been described to bind poly-
nucleotides of dsDNA at regulatory elements including hormone response elements [41, 42]. 
However, the interaction of hnRNPA2 with RNA is much more established. HnRNPA2 has been 
shown to associate with the 21 nt hnRNPA2 response element (A2RE), or the derivative 11 nt 
(A2RE11) which is crucial in the transport of certain mRNAs to the cytoplasm in oligodendrytes 
and neurons [43-45]. The evolutionarily conserved A2RE sequences are also found in other 
transcripts, including; PRM2 (protein subunit of mitochondrial RNase P), MOBP81A (myelin-
associated oligodendrocytic basic protein 81A), GABARα (GABA receptor α subunit), GFAP 
(glial fibrillary acidic protein, an intermediate filament), α-CaMKII (alpha-isoform of 
calcium/calmodulin-dependent kinase II) and ARC (activity-regulated cytoskeleton-associated 
protein) [44-47]. HnRNPA2 can also interact with A2RE-like sequences which are found in a 
region of overlap between the vpr and tat genes of the HIV-1 virus in vitro [48]. Further in vitro 
data show that apart from the A2RE and A2RE-like sequences, hnRNP A2 and its splice variant 
B1 bind UUAGGG sequences [49]. Microarray studies targeted at identifying downstream 
targets of hnRNPA2/B1  found a group of transcripts which did not contain A2REs, suggesting 
that hnRNPA2 may either associate directly with other unidentified RNA binding sequences or 
bind indirectly through associations with other hnRNPs [38]. The hnRNP A2 RNA-recognition 
motifs (RRMs) are both required for high-fidelity binding of the protein to RNA, as a single 
RRM has been observed to lose sequence recognition [50]. 
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 HnRNPA2 has also been implicated in chromosome maintenance and DNA replication. 
HnRNPA2 binds to SET oncoprotein, a key regulator of DNA replication, chromatin remodeling 
and gene transcription. It acts as an inhibitor of protein phosphatase 2A, an enzyme that regulates 
cell proliferatin and differentiation. The unfolding of tetraplex structures, which appears to be 
widespread across the human genome by hnRNPA2 and other hnRNPs may facilitate DNA 
replication [51, 52]. HnRNPB1 has also been shown to participate in DNA repair by associating 
with the DNA-dependant protein kinase (DNA-PK) complex, which mediates the repair of DNA 
double-strand breaks, by inhibiting its activity, whereas hnRNPA1 and A2 have no effect [53]. 
The association of hnRNPA2 with telomeric single-stranded repeat (TTAGGG) has been well 
documented. HnRNPA2 plays an important role in the protection of the telomeric repeat and not 
its complementary sequence from the degradation and hnRNP overexpression is implicated in 
telomere lengthening [54,55].  
 The broad functions of the hnRNPA2 protein also extend to gene transcription. 
HnRNPA2/B1 binds to promoter regions of c-myc, APOE, breast cancer 1 (BRCA1) and 
gonadotropin-releasing-hormone 1 (GnRH1) [56-59]. The exact role of hnRNPA2 as 
transcriptional activator or repressor has yet to be determined, but the mechanisms may be both 
direct and indirect. Pull-down assays using a glutathione s-transferase (GST) tagged p53 
transcriptional activation domain detected hnRNPA2/B1, suggesting the possibility of A2/B1 
forming a complex with p53, which is a multi-targeting transcription factor [38, 60, 61].
 Splicing is an important process of mRNA maturation in which hnRNPs are involved. A 
study characterizing the requirement for a range of hnRNP proteins in alternative splicing of 
apoptotic genes has indicated that the splicing events controlled by hnRNP proteins varies 
between cell lines [62]. HnRNPs regulate pre-mRNA splicing by associating with exonic 
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splicing silencers (ESS) and intronic splicing silencers (ISS), interfering with 3’ splice sites or 
promoting the use of more distal 5’ splice sites [63]. The ability of hnRNPA2 to mediate 
alternative splicing of genes is crucial in the balance of normal and disease state within cells. 
This observation has lead to the investigation of hnRNPA2 mediated alternative splicing within 
certain cancers. Two recently characterized alternative splicing transcripts under hnRNPA2 
control are pyruvate kinase and tumor protein p53 inducible nuclear protein 2 (TP53INP2). As 
described by David et al, pyruvate kinase (PK) has two isoforms which are differentially 
expressed. The PKM1 isoform promotes oxidative phosphorylation, while the embryonic PKM2 
is expressed in growing cells and cancers. Human gliomas, with documented hnRNPA2 
overexpression, preferentially express the PKM2 isoform due to the A2 repressive binding of 
flanking sequences of exon 9, which translates to the PKM2 isoform and a key requirement for 
tumor cell proliferation [64]. Likewise, TP53INP2 alternative splicing by hnRNPA2 was shown 
to be responsible for the migratory capabilities of ovarian carcinoma cells. HnRNPA2 
knockdowns of the same cells showed reduced migration [65]. 
Therefore the concentration of hnRNPA2 weighs heavily on its function. It is no wonder 
then, that the overexpresssion and mislocalization of hnRNPA2 has been described in a 
multitude of cancers, including lung [66], breast [67], colon [40] and stomach carcinomas [68]. 
The overexpression of hnRNPA2/B1 in lung cancer has been investigated as an early detection 
biomarker in pre-cancerous, at risk patients [66]. HnRNPA2 has also been documented to 
interact with CK2, an interaction with implications for cell growth and migration that have yet to 
be fully understood [69]. With the current studies in our lab identifying hnRNPA2 as a 
previously undescribed target of the flavone apigenin, we explore the beneficial possibilities of 
the apigenin-hnRNPA2 interaction on lung cancer cell lines. 
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 The goals of this project were to further study the interaction of apigenin and other 
biologically active flavonoids with hnRNPA2, as well as investigate the physiological effects of 
the flavone-protein interaction on lung cancer. With the use of a FRET nanosensor, we found 
that apigenin and other similarly structured flavonoids bind the hnRNPA2 protein. The treatment 
of lung cancer cell lines with apigenin decreased their migratory abilities but did not have an 
effect on the expression levels of hnRNPA2 at the transcriptional or translational level. Our work 
elucidates the mechanistic pathway of apigenin in lung cancer and provides evidence for the 
potential target of novel anti-cancer and anti-inflammatory therapeutics.     
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2. Materials and Methods 
2.1 Plasmid Construction 
Generation of the fluorescence indicator proteins (FLIP) constructs was accomplished 
using human hnRNPA2
c
 cDNA, amplified by PCR from pET9c-hnRNPA2 vector using forward 
primer PAO-378 (5’-AAGGAAAAAAGCGGCCGCCGGTACCGGCAACCAGGGTG-3’) and 
reverse primer PAO-379 (5’-TTATAGGCGCGCCCACTAGTCTATCGGCTCCTC-3’) to 
generate clones with proper restriction sites to be used in downstream reactions. The PCR 
reactions were carried out with 50 ng of DNA template, 25 pmol forward and reverse primers, 3 
mM MgCl2, 500 µM dNTP, 1x High Fidelity PCR Buffer (Invitrogen, Carlsbad, CA), 1 unit 
High Fidelity Taq polymerase (Invitrogen, Carlsbad, CA) and dH2O.  The PCR was run with 35-
cycles of 30 sec at 95°C, 30 sec at 58°C, and 1 min at 72°C.  PCR fragments were digested first 
with restriction enzyme Not 1 (New England Biolabs, Ipswich, MA), 1X bovine serum albumin 
(BSA), 1X NEB Buffer 3 (New England Biolabs, Ipswich, MA), and dH2O for 20 h at 37
o
C. The 
digestion products were purified utilizing PCR Purification kit (Invitrogen Carlsbad, CA)and 
then digested with Asc1 (New England Biolabs, Ipswich, MA), 1X BSA (New England Biolabs, 
Ipswich, MA), 1X Buffer 4 (New England Biolabs, Ipswich, MA), and dH2O for 3 h at 37
o
C. 
Simultaneously, four micrograms of pENTR/D-TOPO vector was digested with Not1 and 
Asc1 (New England Biolabs, Ipswich, MA), 1X BSA (New England Biolabs, Ipswich, MA), 1X 
Buffer 4 (New England Biolabs, Ipswich, MA), and dH2O for 20 h at 37
o
C. The digestion was 
combined with DNA loading buffer 6X (.25% bromophenol blue and 30% glycerol in H2O) and 
ran on a 1% agarose gel (1 g agarose/ 100 ml 1x Tris-Acetate EDTA Buffer) containing 0.2 
µg/ml ethidium bromide to stain the DNA.  One kb plus DNA ladder was loaded alongside the 
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sample to verify the proper size of the fragments.  The gel was run for 40 min at 100 V.  The 
properly cut pENTR/D-TOPO vector, as determined by size, was excised from the gel and 
purified using the PureLink gel extraction kit (Invitrogen, Carlsbad, CA). 
The hnRNPA2
c 
clones were ligated into the cut pENTR/D-TOPO vector using 50 ng 
hnRNPA2
c 
insert and 50 ng vector, 1X ligation buffer (Roche Basel, Switzerland), autoclaved 
H2O and T4 ligase in a total volume of 10 μl. The ligation was incubated at room temperature for 
2 h and transformed into MAX Efficiency Stbl2™ competent cells (Invitrogen Carlsbad, CA). 
Stbl2 cells were chosen to confront the problematic nature of the multiple repeats in the 
hnRNPA2
c 
sequence. Colonies were picked and screened using enzymes XhoI and SpeI (New 
England Biolabs, Ipswich, MA). 
Positive clones where used in a recombination reaction to move the hnRNPA2
c
 insert into 
the pFLIP vector. Using the homologous recombination sites on the pENTR/D-TOPO vector and 
the His-tagged pFLIP vector, Gateway LR Clonase Kit was used to recombine the hnRNPA2
c
 
fragment into the FLIP construct. The recombination reaction was transformed into MAX 
Efficiency Stbl2™ competent cells (Invitrogen Carlsbad, CA). Selectivity was provided by 
growing cells on Ampicillin containing plates as that is the resistance provided by the pFLIP 
vector. FLIP vectors that did not recombine were eliminated by the ccdB toxic gene contained 
within the recombination sites that should have been recombined out of the pFLIP vector. 
Screening was performed through restriction digestion and positive closes were re-transformed 
into BLR (DE) cells for protein expression. The pFLIP- hnRNPA2
c
 biosensor was created with 
four different fluorescence protein combinations (Table 2). pFLIP vectors were a generous gift of 
Dr. Wolf Frommer. 
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To create different FLIP- hnRNPA2
c
 with improved FRET capabilities, the N-terminal 
and C-terminal linkers between the fluorescent proteins and the hnRNPA2
c
 fragment (Figure 5) 
were preferentially digested out, the DNA fragments purified and then religated. In order to 
remove the N-terminal linker, a restriction digestion was performed using KpnI (New England 
Biolabs, Ipswich, MA) 1X bovine serum albumin (BSA), 1X NEB Buffer 1 (New England 
Biolabs, Ipswich, MA), and dH2O for 3 h at 37
o
C. To remove the C-terminal linker, SpeI 
restriction enzyme was used with the same restriction set up and to remove both linkers, the 
restriction digestion was performed with both KpnI and SpeI simultaneously. All fragments were 
purified using PureLink gel extraction kit (Invitrogen, Carlsbad, CA) after resolution with 1% 
agarose gel. The fragments were then ligated using 50 ng hnRNPA2
c 
insert and 50 ng vector, 1X 
ligation buffer (Roche Basel, Switzerland), autoclaved H2O and T4 ligase in a total volume of 10 
μl. The ligation was incubated at room temperature for 2 h and transformed into MAX Efficiency 
Stbl2™ Competent cells (Invitrogen Carlsbad, CA). After screening for positive clones through 
restriction analysis, positive clones were transformed into BLR(DE)LysS cells for protein 
expression. 
2.2 Induction & Bacterial Cell Lysates 
To test the fluorescence resonance energy transfer (FRET) of the FLIP- hnRNPA2
c
 
nanosensors, inductions were performed to do FRET experiments using bacterial lysates. Single 
colonies of BLR(DE)LysS cells containing appropriate pFLIP-hnRNPA2
c 
constructs were picked 
and grown in 200 ml of LB Broth containing ampicillin (100 μg/ml), tetracycline (10 μg/ml) and 
chloroamphenicol (100 μg/ml). Cultures were grown to an optical density of 0.5 A600 at 37
o
C and 
then induced for two hours at 30
o
C using 1 mM isopropyl 1-thio-β-D-galactopyranoside (IPTG, 
Gold Biotechnology, St. Louis, MO). Cells were harvested at 6,000 g for 5 min and washed in 10 
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ml non-sterile phosphate buffered saline (PBS). Pellets were lysed by sonication (Duty cycle 
30%, Output 5, 5 x 10 pulses) in Tris buffer (20 mM, pH 8) containing protease inhibitors DTT 
(1 mM), PMSF (0.1 mM), and Clap (2 mg/ml of the protease inhibitor cocktail containing 
chymostatin, leupeptin, antipain and pepstatin). Lysates were then centrifuged 15 min at 13,000 
rpm and the supernatant was separated from the pellet. Protein content in the supernatant was 
quantified by SDS-PAGE (12% acrylamide) using a bovine serum albumin (BSA) standard 
curve and visualized through Coomassie blue staining. 
2.3 Protein Purification 
His-tagged CFP-hnRNPA2
c
-YFP protein was obtained through the induction of 1L LB 
Broth cultures as previously described. Bacteria was resuspended in 10 ml Tris buffer (20 mM, 
pH 8) with protease inhibitors and lysed by sonication (refer to Induction & Bacterial Cell 
Lysates section). Lysates were centrifuged at 13,000 rpm for 10 min and the supernatant 
separated from the pellet. The supernatant was combined with 250 μl of 50% slurry nickel beads 
(Ni
+
-NTA-superflow, Qiagen) and incubated at 4
o
C for 2 h on a rocker. The mixture was loaded 
into a previously equilibrated column and washed three times with 1 ml of the Tris buffer. The 
protein was eluted with discontinuous imidazole gradient (20-50 mM). Elution fractions 
containing the CFP-hnRNPA2
c
-YFP proteins were dialyzed in 20 mM Tris buffer, pH 8 for 6 h 
at 4
o
C, in a 1:500 dilution. 
2.4 Fluorescence resonance energy transfer (FRET) Assays 
The ability of the different FLIP-hnRNPA2
c
 proteins to perform the energy transfer was 
screened using lysates. In a 96-well plate, 199 µl of extract were incubated with 1 µl of diluent 
dimethyl sulfoxide (DMSO) of apigenin concentrations from 1-100 µM. Emission spectra of the 
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FLIP-hnRNPA2
c
 was determined using spectrofluorometer plate reader (FlexStation3, Molecular 
Devices) by exciting the N-terminal Cyan fluorescent protein (Table M1,) and recording 
emission over the range of 460nm-600nm. FRET was determined as the intensity of the 
fluorescence emission of the peak corresponding to the C-terminal fluorescent protein (530 nm) 
divided by the intensity of the fluorescence of the N-terminal fluorescent protein (480 nm). The 
reaction was incubated at 37
o
C and time points were taken at 0 h, without flavonoid treatment 
and then at 1 h and 24 h with flavonoid treatment. The ratios of C-terminal fluorescence protein 
peak emission (λemis) divided by N-terminal λemis were calculated and graphed to represent the 
change in FRET of the nanosensor protein in response to flavonoid treatment. CFP-hnRNPA2
c
-
YFP proteins which showed promising FRET capabilities were determined, and the FRET 
analysis was repeated using purified protein nanosensor with the previously described set up. 
Incubation at 37
o
C for 3 h was used for analysis of purified protein nanosensor, after previous 
work performing a time course was showed the 3 h time point representing the best results.  
Table M1. Excitation and emission of fluorescent proteins.  
Fluorescent Protein λext λemis 
Cyan Fluorescent Protein (CFP) 405nm 480nm 
Yellow Fluorescent Protein (YFP) 485nm 530nm 
Green Fluorescent Protein (GFP) 395nm 510nm 
monomeric Kusabira orange (mKO) 510nm 570nm 
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2.5 Dissociation Constants 
 Dissociation constants (KD) of the flavonoid-protein interactions were calculated by 
fitting the YFP/CFP ratio curves to the equation of the binding of a ligand to a protein: 
S = (r – Rmin)/(Rmax-Rmin) = [L]bound/[P]total = n[L]/(KD + [L]) 
where S is saturation; [L] is ligand concentration; [L]bound is concentration of bound ligand; n is 
number of equal binding sites; [FLIP]total is total concentration of FLIP nanosensor; r, ratio; Rmin 
is minimum ratio in the absence of ligand; and Rmax is maximum ratio at saturation with ligand 
[17]. Saturation curves were obtained and KD determined by non-linear regression with the aid of 
GraphPad Prism. Statistical significance between means in FRET experiments were determined 
by one-way ANOVA. 
2.6 Tissue Culture & Treatment 
A549, H1703, H1299 and H2009 (American Type Culture Collection (ATCC) 
Manassas, VA USA) cells were cultured in RPMI (A549) or DMEM (H1703, H1299 and 
H2009) and maintained in a modified atmosphere of 5% CO2 with 10% heat inactivated bovine 
serum (FBS), 100 U/ml penicillin and 100 µl/ml streptomycin (P/S; BioWhittaker, Walkersville, 
MD). 5 x 10
5
 cells were seeded in 1 ml media 16 h before flavonoid treatment. Cells were treated 
with 0, 1, 10 and 50 µM of flavonoid or diluent DMSO for 24 h. Cells were collected by 
centrifugation at 1200 rpm for 5 min, washed in phosphate buffered saline (PBS) and were used 
for either protein or transcriptional analysis. 
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2.7 RNA Isolation & Transcript Analysis 
RNA isolation was performed using the Trizol method. Flavonoid treated mammalian 
cells were pelleted and resuspended in 0.5 ml of Trizol (Invitrogen). One hundred µl of 
chloroform was added to the samples, inverted vigorously and incubated at room temperature for 
2-3 min. The samples were centrifuged at 12,000 rpm for 15 min at 4
o
C to resolve the different 
components of the cells (pink bottom layer representing protein and membrane, white interface 
containing DNA and the clear top layer containing RNA). The top RNA layer was extracted, 
placed in a new tube and 250 µl of isopropanol were added to precipitate RNA. Tubes were 
inverted and incubated at room temperature for 10 min after which samples were centrifuged at 
12,000 rpm for 10 min at 4
o
C. The gel-like pellet was washed in 500 µl of 75% ethanol and 
centrifuged at 12,000 rpm for 5 min at 4
o
C. Pellet was resuspended in 50 µl of diethyl 
dicarbonate (DEPC) treated water (DEPC-H2O). 
Isolated RNA was used to create cDNA for downstream experiments with ThermoScript 
RT-PCR System (Invitrogen). Two hundred  ng of RNA in 2 µl were added to 0.4 µl Oligo(dT), 
0.4 µl Random Hexomers, 1 µl dNTPs and 4.25 µl DEPC-H2O, then incubated at 65
o
C for 5 
min. To the reaction mix was added 4 µl 5X cDNA Synthesis Buffer, 1 µl DTT, 0.1 µl 
RNaseOUT, 0.1 µl ThermoScript RT (15 U/ µl) and 6.25 µl DEPC-H2O. The reaction was 
incubated at 50
o
C for 60 min. Transcriptional expression analysis was carried out through Real-
Time PCR of previously manufactured cDNA. Ten µl SybrGreen (Applied Biosystems) PCR 
master mix was combined with 2 µl cDNA and 250 nmol/L of primers (Table M1) in a total 
reaction mix of 20 µl.  
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Table M2. List of primers utilized for Real-Time PCR.  
PAO-416 hnRNPA2  5'-GGCTACGGAGGTGGTTATGA-3' Forward 
   
PAO-417 hnRNPA2 5'-ACCCCCAAAGTTTCCACTCT-3' Reverse 
  
PAO-296 rRNA 18s 5'-GTAACCCGTTGAACCCCATT-3' Forward 
  
PAO-297 rRNA 18s 5'-CCATCCAATCGGTAGTAGCG-3' Reverse 
  
 
2.8 Western blot 
Extracts from 1 x 10
6
 cells were incubated with Lysis Buffer B (Ingredients: 40 mM 
Hepes, 0.3 M NaCl, 3 mM MgCl2, 0.3 mM EGTA,  0.1% Tween, 50 mM sodium fluoride, 10 
mM sodium glycerophosphate, 5 mM sodium pyrophosphate, 1 mM orthovanadate, 1 mM DTT, 
0.1 mM PMSF, and 2 µg/ml Clap) for 20 min on ice and vortexed 5 sec every 5 min. Lysates 
were sonicated (Duty cycle 30%, Output 5, 3 x 5 pulses) and centrifuged 12,000 rpm for 10 min 
at 4
o
C. Supernatant was extracted and quantified by Bradford assay. Equal amounts of protein 
were loaded and resolved by SDS-PAGE on 12% acrylamide gel at 150 V for 80 min. Proteins 
were transferred to Protran Nitrocellulose Blotting Membranes (0.2 µm, Whatman, USA) for 70 
min at 100 V utilizing transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 20% methanol). 
Membranes were blocked using 5% milk in TBS (10 mM Tris-HCl, 150 mM NaCl, 0.05% 
Tween, pH 7.6) and incubated with anti-hnRNPA2 primary antibody (1:2000 Maker/Brand) to 
detect hnRNPA2 (36 kDa) 16 h at 4
o
C. Anit-mouse secondary antibody conjugated to 
horseradish peroxidase (1:6000, GE, Piscataway, NJ) was added and incubated for 1 hr at rt. 
Proteins were visualized by autoradiography (Amersham Pittsburgh, PA). 
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2.9 Bradford Assay 
Bio-read protein assay reagent 5X (Bio-Rad, Hercules, CA) was diluted to 1X and added 
to standards of 0, 2, 4, 6, and 8 µg BSA to a total 200 µl. Absorbance was measured and used to 
plot a standard curve. One µl of protein sample was added to 199 µl of Bradford reagent, 
absorbance measurements taken at 595 nm. To quantify the protein, a standard cure was 
generated using known increasing concentrations (100 – 1600 µg) of bovine serum albumin 
(BSA) and used to calculate the protein concentration. 
2.10 Migration Assay 
 A549, H1703, H1299 and H2009 lung cancer cell lines American Type Culture 
Collection (ATCC) Manassas, VA USA) were cultured in RPMI (A549) or DMEM (H1703, 
H1299 and H2009) containing 10% heat inactivated bovine serum (FBS), 100 U/ml penicillin 
and 100 µl/ml streptomycin (P/S; BioWhittaker, Walkersville, MD).  5 x 10
5 
cells were seeded 
16 hours before treatment in twelve-well plates. The monolayer of cells attached to the bottom of 
the plate were scratched with a pipette tip, and the detached cells were removed with a PBS wash 
[70]. Media was then added containing  the apigenin treatment (0, 1, 10, and 50 μM), and the 
cultures were  incubated in the modified atmosphere of 5% CO2 at 37 
o
C for 24 h at which point 
the invasive cell migration was photographed at 10x magnification (OlympusIX50 Microscope, 
Olympus QColor3 Camera, and QCapture Pro 6.0 Software).  
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3. Results 
3.1 Generation of a Flavonoid Nanosensor 
To identify direct targets of apigenin, the flavonoid was immobilized to PEGA 
(polyethyleneglycol-polyarcylamide) resin beads which were used to screen a phage display 
breast cancer library. One of the targets identified by pahge display was the heterogenous nuclear 
ribonucleoprotein A2 (hnRNPA2). After several molecular tests, including pull-downs using 
GFP-hnRNPA2 proteins, we were able to show that hnRNPA2 binds to apigenin. In order to 
study the interaction of apigenin with hnRNPA2 a genetically encoded flavonoid nanosensor 
using fluorescence resonance energy transfer (FRET) was developed. FRET based nanosensors 
have previously been used to monitor small molecule to protein interactions [71]. The rationale 
for developing a biosensor is that a nanosensor would allow us to also survey a variety of other 
biologically active flavonoids, to see if they also functioned through hnRNPA2. FRET 
nanosensor technology has previously been utilized in studies monitoring glucose uptake within 
cells [71]. In this case, a glucose binding protein was flanked by two fluorescent proteins, which 
upon the binding of glucose would increase the rate of energy transfer between the two 
fluorescent constituents. This energy change is monitored and quantified for analysis [72]. The 
nanosensor is capable of generating highly useful information based on the concentration of 
ligand, making it possible to not only verify a small molecule to protein interaction but also 
obtain dissociation constants that describe the interaction.   
There are certain molecular qualifications that need to be considered in the development 
of a FRET nanosensor. The first qualification concerns the ability to observe the energy transfer 
between the C-terminal and N-terminal fluorescent proteins flanking the target protein, in our 
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case the apigenin binding domain of hnRNPA2 (hnRNPA2
c
) defined by pull-downs using 
different domains of hnRNPA2  (Figure 2). Secondly, the fluorescent resonance energy transfer 
would change as ligand concentration is increased. For the first property, the fluorescent proteins 
must be in the proximity of 5-10 nm to allow the energy transfer to occur. For the second 
property, the application of apigenin, through binding to hnRNPA2
c
, would cause a 
conformational change in the protein that would change the efficiency of energy between the two 
flanking fluorescent proteins (Figure 3). 
 
The first step in the generation of the apigenin nanosensor was to clone the fragment 
identified by the phage display approach that interacts with apigenin (named throughout the text 
as hnRNPA2
c
) into an entry vector. For this purpose, the human hnRNPA2
c
 fragment was 
amplified through PCR and ligated into pENTR/D-TOPO entry vector. All attempts using 
traditional methods of cloning into the pENTR/D-TOPO entry vector were unsuccessful. To 
overcome these technical difficulties, a normal ligation approach was used. The fluorescence 
indicator protein (FLIP) nanosensor was generated using human hnRNPA2
c
 (Figure 2) cDNA,  
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amplified by PCR from pET9c-hnRNPA2 vector using forward and reverse primers PAO-379 
and PAO-378 respectively and proper restriction enzyme sites Not1 and Asc1 were introduced 
(Figure 4). PCR fragments were digested first with the restriction enzyme Not1, purified utilizing 
PCR Purification kit (Invitrogen Carlsbad, CA) and then digested with Asc1 to provide a 
fragment of 234 bp for subsequent ligation.  
Simultaneously, the pENTR/D-TOPO vector was digested with Not1 and Asc1. Cut 
vector was separated from uncut by agarose gel electrophoresis and the properly cut band was 
excised from a gel and purified (See Materials and Methods). The hnRNPA2
c 
clones were ligated 
into the cut pENTR/D-TOPO vector and transformed into MAX Efficiency Stbl2™ Competent 
cells. Stbl2 cells were chosen to confront the problematic nature of the multiple repeats in the 
hnRNPA2
c 
sequence. Stbl2 genome is ideal to use for repetitive inserts due it mutations in its 
recombinase (recA1), along with a unique set of genetic markers specialized for direct repeat and 
retroviral sequences. Colonies were selected, DNA purified, and clones containing the fragment 
of interest were screened using enzymes Not1 and EcoRV allowing us to assess proper insertion 
and directionality.  
Positive clones where used in a recombination reaction to clone the hnRNPA2
c
 insert into 
the pFLIP vector. Using the homologous recombination sites (attL1 and attL2) on the pENTR/D-
TOPO vector and the His-tagged pFLIP (attR1 and attR2) vector, Gateway LR Clonase Kit was 
used to recombine the hnRNPA2
c
 fragment into the FLIP construct. The recombination reaction 
was again transformed into MAX Efficiency Stbl2™ competent cells. Selectivity for the 
recombination was provided by growing cells on ampicillin plates, as that is the resistance 
provided by the pFLIP vector. pFLIP vectors that did not recombine were eliminated by the ccdB 
(coupled cell division B) toxic gene contained between the recombination sites that should have 
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been recombined out of the pFLIP vector (Figure 4). After DNA purification, screening was 
performed through restriction digestion enzymes XhoI and SpeI. Positive clones were re-
transformed into BLR(DE)LysS, which also have an optimized genome for repetitive inserts, for 
protein expression.  
To create different FLIP-hnRNPA2
c
 proteins with improved FRET capabilities, the N-
terminal and C-terminal linkers (corresponding to the recombination sequences attR1 and attR2) 
flanking the hnRNPA2
c
 insert were preferentially digested out, the DNA fragments purified and 
then re-ligated (Figure 5a). In order to remove the N-terminal linker, a restriction digestion was 
performed using KpnI (Figure 5b). SpeI restriction enzyme was used to remove the C-terminal 
linker and to remove both linkers, the restriction digestion was performed with both KpnI and 
SpeI simultaneously. After digestion with the specific enzymes, the fragments were separated by 
gel electrophoresis (Figure 5c), purified and re-ligated to yield a total of three combinations of 
linkers with distinct FRET capabilities. Removal of the N-terminal linker was designated as 
pFLIP2-2-hnRNPA2
c
, C-terminal excision as pFLIP2-1-hnRNPA2
c
, and excision of both 
designated pFLIP2-3-hnRNPA2
c
. The hnRNPA2
c
 fragment was inserted in between three 
combinations of fluorescence proteins to increase the likelihood of generating a properly 
functioning nanosensor (Table 2).      
 
 
 
 
29 
 
 
  
30 
 
 
3.2 Nanosensor Screening and Protein Expression 
In order to determine the FRET capabilities of the FLIP-hnRNPA2
c
 clones, proteins were 
induced from bacteria as previously described by Fehr et al with some modifications [7]. An 
advantageous feature of our nanosensor clones is that their FRET capabilities were shown to be 
functional in bacterial lysates. First we determined the optimal conditions for FLIP-hnRNPA2
c
 
proteins. Single colonies of BLR(DE)LysS cells containing appropriate pFLIP-hnRNPA2
c 
expression clone were grown with appropriate antibiotics overnight. Cultures were induced for 1, 
2, and 3 h at 30
o
C using isopropyl 1-thio-β-D-galactopyranoside (IPTG). Results from these 
studies indicated that inductions performed at 37
o
C over a 1, 2, and 3 h time course yielded a 
protein that was degraded. However, inductions performed at 30
o
C over the same time points did 
not show degradation of the protein (Figure 6a). Next, we evaluated the solubility of the protein 
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induced. For this purpose, inductions were performed at 30
o
C for 1, 2, and 3h. Bacteria pellets 
were lysed and centrifuged to obtain the bacterial supernatant and pellet fractions. The pellet was 
resuspended in an equivalent volume to the supernatant and fractions of both were loaded onto a 
SDS-PAGE gel (Figure 6b). Gels stained with Commassie showed a polypeptide of 
approximately 64 kDa that was primarily found in the pellet or insoluble fraction. While we 
observed an increase in the expression of the FLIP proteins over the 3 h period, the amount 
found in the soluble fraction remained similar during all times of induction. Therefore, taken 
with the results from the different temperature studies, we determined that the optimal conditions 
to obtain soluble pFLIP-hnRNPA2
c 
were for 2 h of IPTG induction at 30
o
C. Next, using the 
conditions of induction determined, the different pFLIP clones were induced and the soluble 
fraction of protein quantified by SDS-PAGE using a standard curve generated by loading 
increasing concentrations of bovine serum albumin (BSA and visualized through Coomassie blue 
staining (Figure 6c). 
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The ability of FLIP-hnRNPA2
c
 proteins to perform the energy transfer was tested. For 
this purpose, lysates of bacteria expressing the clones listed on Table 2 were incubated with 1 µl 
of diluent dimethyl sulfoxide (DMSO) or apigenin at concentrations ranging from 1-25 µM. 
Emission spectra of the FLIP-hnRNPA2
c
 was determined using spectrofluorometry by exciting 
the N-terminal fluorescent protein (Table 3) and recording emission over the range of 460-600 
nm. FRET was determined as the intensity of the fluorescence emission of the peak 
corresponding to the C-terminal fluorescent protein (ex. YFP: 530 nm) divided by the intensity 
of the fluorescence of the N-terminal fluorescent protein (ex. CFP: 480 nm). The reaction was 
incubated at 37
o
C and time points were taken at 0 h, without flavonoid treatment and then at 1 
and 24 h (results shown at 1h) with flavonoid treatment. The ratios of C-terminal fluorescence 
protein peak emission (λemis) divided by N-terminal λemis were calculated and graphed to 
represent the change in FRET of the nanosensor protein in response to flavonoid treatment 
(Figure 7). Of the eight constructs generated, only four possessed the first property of a 
nanosensor which is efficient energy transfer between the fluorescent proteins (FLIP-2-
hnRNPA2
c
, FLIP-2-2-hnRNPA2
c
, FLIP-2-3-hnRNPA2
c
 and FLIP3-hnRNPA2
c
). Of those, only 
FLIP-2-3-hnRNPA2
c 
(Figure 7), showed a significant change in FRET ratio with increasing 
apigenin concentrations. Thus, we focused on this construct for subsequent experiments. 
  In order to augment the change in FRET ratio, we increased the concentrations of 
apigenin (0, 1, 5, 10, 25, 50, 100 µM), as well as recording FRET at 0, 1, 3, 12 and 24 h. These 
studies improved the variability observed with bacterial lysates allowing more consistent results. 
With the new conditions, we satisfied the second qualification of the FRET nanosensor which 
was a dose dependant change in FRET with increasing apigenin concentration (Figure 8).  This 
suggested that the 3h incubation allowed for sufficient interaction of the protein and ligand, 
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while at the same time preserving the 
FRET capabilities of the protein, as at 
later times, FRET was diminished. In 
order to improve our results, and 
overcome variability possibly caused by 
the interaction of the FRET nanosensor 
with the multiple proteins present in the 
bacterial lysates, we decided next to 
purify FLIP-2-3-hnRNPA2
c
. 
Native FLIP-2-3-hnRNPA2
c
 (Figure 9a) protein was purified by Ni
2+
 - NTA affinity 
column chromatography. Recombinant protein was purified from lysed bacteria using affinity 
column chromatography for the 6X Histidine tag on the pFLIP-2-3-hnRNPA2
c
 vector (described 
in Materials and Methods).   The protein was eluted using a discontinuous imidazol gradient and 
run on a SDS-PAGE gel.  The gel was stained with coomassie and FLIP-2-3-hnRNPA2
c
 was 
found eluting at a concentration of 20 and 50 mM imidazole (Figure 9b).  These imidazole 
fractions that contained FLIP-2-3-hnRNPA2
c
 were dialyzed and used for subsequent 
experiments. The purified FLIP-2-3-hnRNPA2
c
 nanosensor was used to determine the 
association of hnRNPA2 with apigenin.  
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3.3 Multiple Flavonoids Interact with hnRNPA2 
To determine the interactions of the purified FLIP-2-3-hnRNPA2
c
, one micromolar 
nanosensor was incubated with increasing concentrations of apigenin (0, 1, 5, 10, 25, 50, 100 
µM) for 3 h at 37
o
C, at which time spectrofluorometry was performed and FRET ratios were 
calculated. The results yielded by the FRET nanosensor incubation with apigenin showed that 
there was an increase in FRET between the two fluorescent proteins in response to increasing 
concentrations of apigenin. We conclude therefore that there is an interaction between hnRNPA2 
and apigenin (Figure 10a). Further, the data calculated for the YFP/CFP ratios were transformed 
to saturation curves as described in Materials and Methods. The saturation curves allowed for the 
calculation of dissociation constants (KD). For apigenin, the calculated KD with the hnRNPA2 
nanosensor was 22.9 + 7.70 µM.  
37 
 
To determine if other structurally similar flavonoids also interacted with hnRNPA2, we 
incubated indicated flavonoids with the FRET nanosensor. In contrast to apigenin, naringenin 
(Figure 10c), an apigenin precursor which does not share the physiological benefits of apigenin 
[27] and differs in structure by a double bond between the two and three carbon positions (Figure 
2a), did interact with the FRET nanosensor. Naringenin belongs to the flavonone family of 
flavonoids, as does eriodictyol (Figure 10c), which did not show binding affinity for the 
nanosensor and consequently hnRNPA2. Continuing to investigate similar flavonoids to 
apigenin, we tested luteolin. Luteolin is also classified as a flavone (Table 1), differing from 
apigenin with an extra alcohol group on the 3’ carbon (Figure 2a), which showed binding to 
hnRNPA2 (KD = 131 + 78.8 µM, Figure 10b). However the addition of a methyl group to the 
alcohol on the 3’ carbon, transforming the molecule into chryseriol, diminishes the interaction 
(Figure 10b).  
The apigenin glucosides, apigein-7-O-glucoside and apigenin-6-C-glucoside were also 
tested for their ability to bind hnRNPA2. The 7-O-glucoside showed no binding (Figure 10d) 
while the 6-C-glucoside proved to have a more significant interaction to hnRNPA2 (Figure 10d) 
with a KD of 60.88 + 24.14 µM. This observation highlights the importance of the 7-O group in 
the apigenin interaction with hnRNPA2, as the role of glucose does not seem to be purely steric, 
as shown by the 6-C-glucoside binding. The testing of the glucosides gives insight at to the bio-
availability of active apigenin, since the most abundant forms of apigenin are found as 
glucosides. Interestingly, the flavonols quercetin (KD = 126 + 60.2 µM) and kaempferol (KD = 
27.1 + 12.2 µM, Figure 10e), which share similar biological activities as apigenin also showed  
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bindig to hnRNPA2. This suggests that they may act in a similar manner as apigenin through 
hnRNPA2. Alternatively, no binding was detected for the biologically isoflavone genistein 
(Figure 10f). 
Flavonoids such as flavopiridol are currently used in clinical treatment of cancers, and are 
known to work through their interaction with cyclin dependant kinases [73]. Here we tested the 
ability of flavopiridol to interact with hnRNPA2. We found that flavopirol (Figure 10g), does not 
bind to hnRNPA2, suggesting that it works through mechanisms independent of hnRNPA2, as 
previously known. Together, the results obtained from the flavonoid nanosensor suggest that 
apigenin and molecularly similar flavonoids bind to hnRNPA2, however slight modifications in 
structure are capable of disrupting the interaction.  
3.4 Apigenin and Invasive Lung Cancer Migration 
It has been previously reported that there is an over-expression of hnRNPA2 and its 
splice variant B1 in all histological subtypes of lung cancers [4], a fact which has lead 
investigators to explore the role of hnRNPA2 in lung cancer progression and migration. Along 
with the potential of hnRNPA2 over-expression to be used as an early biomarker for lung cancer, 
there is the possibility of attacking hnRNPA2 as a therapeutic approach for lung cancer. 
Microarray data of hnRNPA2/B1 silencing in the adenocarcinoma cell line A549 shows that 
silencing effects genes involved in cell migration, cellular development and cell death [66]. 
Other implications of hnRNPA2 involvement in cell migration have exposed the alternative 
splicing abilities of A2 of genes which affect cell migration, such as T53INP2 [65]. In the study 
of T53INP2 alternative splicing, hnRNPA2 knockdowns showed both the alternative splicing of 
the gene, correlated with reduced migration of cells [65]. With these previous results, and the 
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interaction of apigenin with hnRNPA2, we first investigated the effects of apigenin on hnRNPA2 
expression levels and cell migration. Four different non-small lung cancer (NSCLC) cell lines, 
representing both different stages and histological subtypes, A549 (adenocarcinoma; Stage 1), 
H2009 (adenocarcinoma; Stage IV), H1703 (Squamous cell carcinoma) and H1299 (Large cell 
carcinoma) were treated with 0, 1, 10, and 50 μM apigenin for 24 h. mRNA expression levels of 
hnRNPA2 were evaluated using Real-Time PCR, using 18s ribosomal RNA as a control. We 
found no significant change in the steady state mRNA levels of hnRNPA2 in cells treated with 
increasing concentrations of apigenin (Figure 11a). in addition, cell lysates showed no difference 
in the protein levels of hnRNPA2 in the presence of apigenin (Figure 11b). This suggests that 
apigenin’s interaction with hnRNPA2 does not affect the expression levels of the protein. 
However, at the 50 μM concentration we found that apigenin decreased hnRNPA2 expression in 
mouse macrophages and THP-1 monocytic leukemia cells (not shown).  
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We next studied the effect of apigenin in migration, a phenotype associated with 
hnRNPA2. For this purpose, non-small lung cancer (NSCLC) cell lines were used in scratching 
assays. The monolayer of cells seeded 16 h before treatment were separated using a pipette tip, 
creating a space or wound. At this point, apigenin was added at (0, 1, 10, and 50 μM) for 24 h 
and then cells were photographed at different times to observe the extent of invasive migration. 
Of the four cell lines, all showed a dose dependant decrease in cell migration when cultured in 
the presence of apigenin compared to the control (Figure 12). The stage IV adenocarcinoma cell 
line H2009 had the most aggressive migratory abilities, almost completely closing the wound. 
However, we found that there is a larger response to apigenin in the later stage IV 
adenocarcinoma cell line H2009 over the earlier stage A549 with increasing apigenin 
concentrations. H1703 squamous cell carcinoma cells showed the second most aggressive 
migration, followed by H1299, large cell carcinoma. All together, apigenin was able to decrease 
the amount of migration in the lung cancer cell lines. We determined that the more aggressive 
the cell line, the greater effect apigenin had on migration. We also observed different 
morphology in all of the lung cancer cells in response to apigenin treatment. The morphology of 
the cells was of a more compact and less confluent nature, consistent with studies of cell 
migration in hnRNPA2 knockouts [65]. These results show the potency of apigenin to decrease 
the invasive migration of lung cancers, with the most significant effect on the aggressive Stage 
IV adenocarcinoma which reeks havoc on the body through its destructive migratory abilities.  
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4. Discussion 
 The flavonoid apigenin, which is abundantly distributed in a variety of green-leaf plants 
and vegetables, has many beneficial health properties [10, 11]. These include anti-inflammatory, 
anti-proliferative and anti-carcinogenic properties [24-26]. The aptitude of apigenin and similar 
compounds to poses these medically relevant abilities has been long known, however an 
understanding of the mechanisms by which they act has been lacking. Flavonoids, particularly 
flavonols and flavones have been shown to interact with extracellular proteins collagen and BSA 
with dissociation constants (KD) in the 5 – 100 µM range [74]. In order to address the necessity 
of knowledge in the mechanisms by which flavonoids work, we utilized a phage-display library 
with next-generation sequencing to identify, amongst others, the heterogeneous nuclear 
ribonucleoprotein A2 (hnRNPA2) as a direct target of apigenin. Phage-display is an ideal 
technique to find cellular targets of small molecules because of the ability to screen a large 
cohort of proteins in an efficient manner. Phage-display studies have been used to better 
characterize the cellular interactions of small molecules such the chemotherapeutic paclitaxel 
[75]. Paclitaxel was known to arrest mitosis and induce apoptosis, however there was no known 
molecular target by which it acted to induce apoptosis. Through phage-display experiments the 
anti-apoptotic protein Bcl-2 was identified as a paclitaxol-binding protein [75]. Similarly, 
apigenin has lacked a cellular target which would shed light onto its mechanism of action. The 
identified apigenin target, hnRNPA2 is one of approximately 20 major polypeptides in the 
hnRNP family which are responsible for mRNA metabolism, as well as other actions involving 
interactions with poly-nucleotides [38]. Notably, hnRNPA2 has been reported to be 
overexpressed in all histological subtypes of lung cancer as well as a multitude of other 
carcinomas, making the discovery that it interacts with apigenin even more significant [66]. With 
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the description of a novel target for the flavonoid apigenin, we investigated if other flavonoids, 
which include a great diversity of molecules, may function through a similar mechanism.  
achieve such a goal, we developed a flavonoid nanosensor capable of distinguishing which 
flavonoids interact with hnRNPA2 as a possible means of exerting their physiological effects. 
Therefore, we divulged deeper into the interaction of hnRNPA2 with flavonoids to describe 
novel observations with implications for both cancer and inflammation. 
 The identified target was validated using pull downs in cellular extracts. In addition, to 
validate and define the affinity of the interaction between apigenin and hnRNPA2, we 
constructed a genetically encoded FRET nanosensor. The FRET nanosensor would allow us to 
both monitor the interaction of apigenin to hnRNP, as well as give us the capability to evaluate a 
variety of flavonoids and their ability to interact with the protein. In constructing the nanosensor, 
we cloned human hnRNPA2
C
 (Fig. 3) into the pFLIP2 vector in frame between the regions 
coding for the N-terminal-CFP and C-terminal-YFP fluorescent proteins. Our studies with the 
FRET nanosensor validated the hnRNP A2 and apigenin interaction (KD = 22.9 + 7.70 µM) as 
well as that of flavonoids including luteolin (KD = 131 + 78.8 µM), quercetin (KD = 126 + 60.2 
µM) and kaempferol (KD = 27.1 + 12.2 µM). Incubation of the nanosensor with glucosides of 
apigenin, which are the most abundant natural forms, gave us insight into the bio-aviliblity of 
apigenin to serve its physiological functions. The addition of a glucose to the apigenin molecule 
significantly decreased binding of apigein-7-O-glucoside and apigenin-6-C-glucoside (KD = 
60.88 + 24.14 µM). The FRET-nanosensor also provided insight into the structural and 
functional groups that were most important for apigenin binding to hnRNPA2. This is an 
attractive feature of the nanosensor which could be exploited to design molecules similar to 
apigenin that would have a higher affinity for hnRNPA2, thereby, attaining a therapeutic with 
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comparable potency to that of current chemotherapeutics such as the clinically used flavonoid-
based agent flavopiridol, which does not bind to hnRNPA2, but instead works through 
interactions with cyclin-dependant kinase 9 (Cdk9) to arrest cell division [73]. FRET-based 
nanosensors are currently used to measure the uptake of vital sugars in multiple organisms [75], 
technology that can be extended further to measure levels of appropriate flavonoids in solution. 
This utility could become a tool to be refined for efficient and widespread studies in measuring 
dietary and supplementary uptake of flavonoids within patients.  
 In addition, we atempted to follow up on previously published data on hnRNPA2 siRNA 
experiments, which had showed a decrease in the invasive migration of lung cancer cell lines 
[65]. We first looked into the effect apigenin-hnRNPA2 interaction on hnRNPA2 expression, as 
a possible point of hnRNPA2 regulation by apigenin. However, we did not observe a change in 
hnRNPA2 expression levels at the transcriptional or translational level (Figure 10). We 
continued with the migration studies to investigate whether the flavonoid-protein interaction 
would still yield a phenotype observed by the hnRNPA2 knockdown studies. Indeed, we found 
that the four non-small lung cancer cell lines we studied (A549, H2009, H1703 and H1299) all 
showed a decrease in migration inversely proportional to apigenin treatment (Figure 11). This 
suggests to us that the interaction between the apigein and the hnRNPA2, specifically with the 
Glycine-rich domain (GRD) does not affect the amount of hnRNPA2 in the cell, however, by 
binding to the GRD and consequently the protein-protein binding domain of A2, apigenin 
interferes with ability of the protein to dimerize and perform its functions.  
In this role, apigenin is serving as a regulator of hnRNPA2 and its downstream effects. 
The apigenin bound, less physiologically active effects of hnRNPA2 may include the differential 
alternative splicing reported for the pyruvate kinase (PK) and TP53INP2 genes involved in 
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cancer growth and migration respectively, to their non-carcinogenic isoforms (Figure 13. Model 
of apigenin molecular mechanisms). Another possibility by which apigenin bound to hnRNPA2 
could be impacting cell migration is through its anti-inflammatory effects. In the inflammatory 
pathway, when ligands such as lipopolysaccharide (LPS) bind to toll-like receptors (TLR), it 
triggers a signaling cascade which culminates in the phosphorylation of the IKK complex by 
casein kinase 2 (CK2) and subsequent release of the transcription factor NF-κB (Figure 13). NF-
κB upregulates chemokine receptor CXCR4, which when bound by its ligand stromal cell-
derived factor (SDF-1) plays a major role in cellular movement [76]. The CXCR4/SDF-1 axis is 
involved in embryogenesis and organogenesis and plays an important role in directing 
hematopoetic/lymphopoeitic stem cells to inflammation sites [77-79]. Interestingly, higher 
CXCR4 increases metastasis of lung cancer where reduced expression and localization of 
CXCR4 in the nucleus correlates with a better outcome [80]. Pan et al, proposed that the 
observed CXCR4 mediated migration of cells may be related to CXCR4-mediated nuclear export 
of hnRNPA2/B1 [81]. Therefore, triggering of inflammation leads to the activation of NFκB, 
causes the upregulation of CXCR4, increases the extranuclear concentration of hnRNPA2/B1 
and causes the migration of cells and other effects of hnRNPA2/B1 overexpression. Apigenin 
interferes with this pathway by blocking the effects of the hnRNPA2/B1 overexpression, and 
down-modulating its pro-carcinogenic effects.  
Further evidence for this model comes from the interaction of hnRNPA2 and CK2. CK2 
phosphorylation of hnRNPA2 represents a post-translational modification of hnRNPA2 with yet 
unknown consequences. It has also been shown that hnRNPA2 associates with the catalytic 
subunit of CK2 [82]. As previously stated, CK2 is responsible for the phosphorylation of the 
IKK complex to release NF-κB transcription factor, and may be another point where apigenin 
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binding to hnRNPA2 can be modulating the protein’s interaction with CK2. This step in the 
pathway is also directly impacted by apigenin’s inhibition of CK2. However of the multitude of 
interactions described need to be further investigated to assess their outcomes on cell migration, 
proliferation and inflammation. It would seem that the overexpression and differential 
localization of hnRNPA2 is the consequence of multiple pathways, and extranuclear localization 
of hnRNPA2 is associated with a poor prognosis. Interestingly, internal data suggests that 
apigenin is also localized in the cytosol and not the nucleus. HnRNPA2 is heavily involved in 
cell migration of both normal and cancer cells. However under cancerous conditions, hnRNPA2 
expression does not return to normal after proper migration [83]. We have shown that apigenin is 
able to bind hnRNPA2 and that apigenin treatment inhibits migration of cells. We therefore 
conclude that apigenin binding to hnRNPA2 inhibits the proteins pro-migratory effects.  
For our future directions, we will delve deeper into the physiological relevance of the 
apigenin-hnRNPA2 interaction. We will do this firstly by introducing the FRET-based 
nanosensor into mammalian cells and monitoring apigenin uptake and interaction and binding to 
the nanosensor in vivo to provide further evidence of the stable protein-ligand interaction. Also, 
we need to look into the alternative splicing by hnRNPA2 in response to apigenin treatment, to 
see if we can replicate the same results as presented by the studies with pyruvate kinase (PK) and 
TP53INP2 of hnRNPA2 knockdowns. This will give us more definitive proof of the observed 
anti-migratory and anti-proliferative phenotypes of apigenin on lung cancer cell lines. Finally, 
hnRNPA2 and its functions are not able to explain all of the physiological roles of apigenin. 
Thus, we must also investigate the other direct targets of apigenin identified by our phage-
display studies, continuing to validate more targets, in order to provide a holistic representation 
of apigenin’s effects.  
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